Your Cart

Dog Umbilical Cord-derived Mesenchymal Stem Cells – Female

$829.00

UC-MSCs derived from the umbilical cord tissue of a neonatal (day 0) female dog

1 x 106 cells

Please see our statement on why passage numbers can be misleading.

Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are multipotent stem cells with a high capacity for self-renewal. Umbilical cord stem cells can develop into specialized cells of the body such as chondrocytes, osteoblasts, and adipocytes, and their easy accessibility, exceptional genomic stability, and capacity for tissue repair with few immunological and ethical issues make them a favorable cell type for experimental and clinical use. Stem cells from umbilical cord have advantages over traditional sources of MSCs, including ease of collection, faster self-renewal, longer multipotency, and additional immunosuppressive properties, making them potentially beneficial in regenerative medicine and tissue engineering.

Canine umbilical cord-derived MSCs were isolated from the umbilical cord tissue of a neonatal (day 0) female canine. The cells are cultured, passaged for purity, cryopreserved, and delivered frozen. Each vial contains 1 x 106 cells in 1 mL volume. Canine umbilical cord stem cells are characterized by flow cytometry for CD90, CD105, CD44, CD45, and CD34. UC-MSCs are negative for mycoplasma, yeast, fungi, and bacteria. Cells are assured to further culture using the protocol provided by JangoCell.

Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are also known as: UCMSCs, umbilical cord-derived mesenchymal stromal cells, umbilical cord medicinal signaling cells, umbilical cord stem cells, perinatal stem cells, umbilical cord-derived MSCs, umbilical cord mesenchymal stem cells, umbilical cord mesenchymal stromal cells.

Additional information

Species/Breed

Tissue

Age

,

Sex

JangoCell Statement on Passage Number

While passage number is the de facto metric used for determining cell proliferation capacity, the actual capacity is dependent upon the total number of cell divisions (or population doubling number (PDN)) that a particular cell type can undergo. This can be illustrated with a simple example. Since stem cells are typically passaged upon reaching confluence, cells grown at low confluence in a flask or in a large vessel such as a bioreactor (large surface area to cell number) will require many more doublings to reach confluence before they are ‘passaged’ than cells seeded at high confluence. This can result in low passage numbers, but a cell population with more limited capacity for further cell division. Therefore, passage number is not the most reliable means of determining future cell proliferation capacity after purchase.

For these reasons, and to provide transparency concerning our cell products, JangoCell will express future cell division capacity, or the number of times that our cells will be able to divide and double in number after purchase (after thaw), in terms of population doubling number (PDN). We will express the current cell division number, or the number of times that our cells have already divided and doubled in number before cryopreservation, in terms of population doubling level (PDL). JangoCell’s primary stem cells when plated at ~20% confluency will display a PDN between 30-40 when cultured using the protocol recommended by JangoCell for each specific cell type.

Please see our page on passage number under Technical Resources for more information.

Catalog Number UC-MSC-DBF-05
Lot Number Included with shipment
Country of Manufacture USA
Quantity 1 x 106 cells/vial
Storage Immediately transfer cells from dry ice to liquid nitrogen upon arrival.
Shipping Info Dry ice; Overnight shipping
Also Known As UCMSCs, umbilical cord-derived mesenchymal stromal cells, umbilical cord medicinal signaling cells, umbilical cord stem cells, perinatal stem cells, umbilical cord-derived MSCs, umbilical cord mesenchymal stem cells, umbilical cord mesenchymal stromal cells.
Product Use This product is for research use only. It is not approved for use in humans, animals, or for diagnostic procedures.
References Corrao S, La Rocca G, Lo lacono M, Corsello T, Farina F and Anzalone R. Umbilical cord revisited: from Wharton’s jelly myofibroblasts to mesenchymal stem cells. Histology and Histopathology. 2013; 28(10):1235-1244. doi: 10.14670/HH-28.1235. Epub 2013 Apr 18.

 

Kang BJ, Ryu HH, Park SS, Koyama Y, Kikuchi M, Woo HM, Kim WH and Kweon OK. Comparing the osteogenic potential of canine mesenchymal stem cells derived from adipose tissues, bone marrow, umbilical cord blood, and Wharton’s jelly for treating bone defects. Journal of Veterinary Science. 2012; 13(3):299-310. doi: 10.4142/jvs.2012.13.3.299. Epub 2012 Sep 20.

 

Nagamura-Inoue T and He H. Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility. World Journal of Stem Cells. 2014; 6(2):195-202. doi: 10.4252/wjsc.v6.i2.195. Epub 2014 Apr 26.

Contact us for the technical documents on this product.

Does your published paper include JangoCell products?

If you publish a paper that includes any of our products, tell us and we will reward you with ONE Free JangoCell product.

That’s right – get 100% off a single JangoCell branded item in our store. Simply contact us and we’ll supply you with a coupon code.

Subscribe to Our Newsletter
Be the first to know about our latest products, specials, and research findings.